At least 15,611 Xarelto lawsuits are now pending in the federal litigation currently underway in the U.S. District Court, Eastern District of Louisiana. The proceeding is set to begin its first bellwether trial later this month, with additional trials scheduled to be convened in May, June and July.

First Trial Involves Gastrointestinal Bleeding Allegations

According to, all of the cases pending in Louisiana were filed on behalf of Xarelto users who suffered serious episodes of internal bleeding and other side effects allegedly caused by the blood-thinning medication. The litigation is set to begin its first bellwether trial on April 24th in New Orleans. Joseph Boudreaux, Jr., the plaintiff in that case, is alleged to have experienced a severe gastrointestinal bleed just a month after he started using Xarelto.

Bellwether trials are an important milestone in any federal multidistrict ligation, as the outcomes of such cases are intended to provide the parties with some insight into how juries might rule in lawsuits that put forth similar questions of fact. The Xarelto litigation is expected to convene three additional bellwether trials this summer, the second of which will begin on May 30th in New Orleans. The third will take place in the U.S. District Court, Southern District of Mississippi in June; while the fourth will begin in July in the U.S. District Court, Northern District of Texas.

Xarelto defendants include Bayer AG, which manufactures the drug, as well as Johnson & Johnson’s Janssen Pharmaceuticals unit, which markets the medication in this country. Xarelto was approved by the Food & Drug Administration in October 2011. U.S. sales of the drug hit $549 million in the second quarter of 2016, making it  one of Johnson & Johnson’s best-performing medications.

Individuals pursuing Xarelto lawsuits claim that that  defendants failed to provide adequate warnings about its risks, and wrongly marketed Xarelto as a superior alternative to a much-older blood thinner called warfarin. Among other things, their filings point out that hemorrhaging caused by warfarin can be stopped via the administration of vitamin K. However, there is currently no approved antidote to reverse Xarelto bleeding side effects.

Xarelto Attorneys

Bernstein Liebhard LLP is representing plaintiffs in Xarelto lawsuits. If you or a loved one suffered a bleeding-related injury while using this medication, please call 877-779-1414 to learn more about your legal rights.

Published April 3, 2017 by